microRNA在乳腺癌耐药中的作用

doi:10.11904/j.issn.1002-3070.2017.03.017

摘要/Abstract

摘要： 乳腺癌是危害全球女性健康的主要疾病,而乳腺癌患者对现有治疗方法产生获得性耐药成为目前乳腺癌临床治疗所面临的难题。微小RNA(miRNA)是一种内源性的非编码RNA,它参与调控多种生物学过程,包括细胞增殖、侵袭、转移、上皮间质转化和耐药等。获得性耐药包含多种复杂机制,可通过特定miRNA的异常表达影响细胞相关蛋白的表达、抗肿瘤药物与相应靶点的结合以及凋亡相关途径引起乳腺癌耐药。本文将重点关注在乳腺癌内分泌治疗、化疗、分子靶向治疗发生获得性耐药中表达异常的miRNA。相信miRNA能够成为乳腺癌临床诊断与治疗以及对抗获得性耐药的生物标志物和新的治疗靶点。

关键词: 乳腺癌, miRNA, 耐药

Abstract: Breast cancer is a major disease which threatens the health of women around the world.Breast cancer patients have acquired resistance to existing treatment methods become the current clinical problems.MicroRNA(miRNA)is an endogenous non-coding RNA that participates in the regulation of a variety of biological processes,including cell proliferation,invasion,metastasis,epithelial interstitial transformation and drug resistance.Acquired resistance includes a variety of complex mechanisms that can affect the expression of cell-associated proteins through the abnormal expression of specific microRNAs,the binding of antineoplastic agents to the corresponding target,and the pathways associated with apoptosis.This article will focus on the expression of abnormal microRNA in acquired drug resistance which was caused by endocrine therapy,chemotherapy and molecular targeted therapy of breast cancer.miRNAs are considered as promising biomarkers and targets for diagnosis,treatments for acquired drug resistance of breast cancer.

Key words: Breast cancer, microRNA, Drug resistance

中图分类号:

R737.9

黄剑，庞慧，宋雨航综述，蔡莉审校. microRNA在乳腺癌耐药中的作用[J]. 实用肿瘤学杂志, 2017, 31(3): 272-276.

HUANG Jian,PANG Hui,SONG Yuhang,CAI Li. The role of microRNA in drug resistance of breast cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(3): 272-276.

参考文献

1 Ahmad A.Pathways to breast cancer recurrence[J].ISRN Oncol,2013,2013:290568.
2 Wu X,Somlo G,Yu Y,et al.De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer[J].J Transl Med,2012,10:42.
3 Garofalo M,Croce CM.MicroRNAs as therapeutic targets in chemoresistance[J].Drug Resist Updat,2013,16(3-5):47-59.
4 Di Leva G,Croce CM.Roles of small RNAs in tumor formation[J].Trends Mol Med,2010,16(6):257-267.
5 Lee Y,Ahn C,Han J,et al.The nuclear RNase III Drosha initiates microRNA processing[J].Nature,2003,425(6956):415-419.
6 Takahashi RU,Miyazaki H,Ochiya T.The roles of microRNAs in breast cancer[J].Cancers(Basel),2015,7(2):598-616.
7 Sabnis GJ,Goloubeva O,Chumsri S,et al.Functional activation of the estrogen receptor-alpha and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole[J].Cancer Res,2011,71(5):1893-1903.
8 Ma CX,Adjei AA,Salavaggione OE,et al.Human aromatase:gene resequencing and functional genomics[J].Cancer Res,2005,65(23):11071-11082.
9 Hayes EL,Lewis-Wambi JS.Mechanisms of endocrine resistance in breast cancer:an overview of the proposed roles of noncoding RNA[J].Breast Cancer Res,2015,17:40.
10 Iorio MV,Casalini P,Piovan C,et al.Breast cancer and microRNAs:therapeutic impact[J].Breast,2011,20(Suppl 3):63-70.
11 Lyng MB,Laenkholm AV,Sokilde R,et al.Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant tamoxifen mono-therapy:a DBCG study[J].PLoS One,2012,7(5):e36170.
12 Miller TE,Ghoshal K,Ramaswamy B,et al.MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1[J].J Biol Chem,2008,283(44):29897-29903.
13 Cittelly DM,Das PM,Spoelstra NS,et al.Downregulation of miR-342 is associated with tamoxifen resistant breast tumors[J].Mol Cancer,2010,9:317.
14 Shi W,Gerster K,Alajez NM,et al.MicroRNA-301 mediates proliferation and invasion in human breast cancer[J].Cancer Res,2011,71(8):2926-2937.
15 Dunn C,Keam SJ.Letrozole:a pharmacoeconomic review of its use in postmenopausal women with breast cancer[J].Pharmacoeconomics,2006,24(5):495-517.
16 Masri S,Liu Z,Phung S,et al.The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells[J].Breast Cancer Res Treat,2010,124(1):89-99.
17 Vilquin P,Donini CF,Villedieu M,et al.MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer[J].Breast Cancer Res,2015,17:13.
18 Buzdar AU,Robertson JF.Fulvestrant:pharmacologic profile versus existing endocrine agents for the treatment of breast cancer[J].Ann Pharmacother,2006,40(9):1572-1583.
19 Di Leo A,Jerusalem G,Petruzelka L,et al.Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer[J].J Clin Oncol,2010,28(30):4594-4600.
20 Xin F,Li M,Balch C,et al.Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance[J].Bioinformatics,2009,25(4):430-434.
21 Rao X,Di Leva G,Li M,et al.MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways[J].Oncogene,2011,30(9):1082-1097.
22 Yu X,Luo A,Liu Y,et al.MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy[J].Mol Cancer,2015,14:208.
23 Pan ST,Li ZL,He ZX,et al.Molecular mechanisms for tumour resistance to chemotherapy[J].Clin Exp Pharmacol Physiol,2016,43(8):723-737.
24 Zhu Y,Yu F,Jiao Y,et al.Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5[J].Clin Cancer Res,2011,17(22):7105-7115.
25 Tryndyak VP,Beland FA,Pogribny IP.E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells[J].Int J Cancer,2010,126(11):2575-2583.
26 Bao L,Hazari S,Mehra S,et al.Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298[J].Am J Pathol,2012,180(6):2490-2503.
27 Zhong S,Li W,Chen Z,et al.MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells[J].Gene,2013,531(1):8-14.
28 Wang H,Tan G,Dong L,et al.Circulating MiR-125b as a marker predicting chemoresistance in breast cancer[J].PLoS One,2012,7(4):e34210.
29 Gu X,Li JY,Guo J,et al.Influence of miR-451 on drug resistances of paclitaxel-resistant breast cancer cell line[J].Med Sci Monit,2015,21:3291-3297.
30 Sha LY,Zhang Y,Wang W,et al.MiR-18a upregulation decreases Dicer expression and confers paclitaxel resistance in triple negative breast cancer[J].Eur Rev Med Pharmacol Sci,2016,20(11):2201-2208.
31 Zhao ZL,Cai Y,Wang YY,et al.Effects of miRNA-21 on paclitaxel-resistance in human breast cancer cells[J].Zhejiang Da Xue Xue Bao Yi Xue Ban,2015,44(4):400-409.
32 Brufsky A.Trastuzumab-based therapy for patients with HER2-positive breast cancer:from early scientific development to foundation of care[J].Am J Clin Oncol,2010,33(2):186-195.
33 Baselga J,Gelmon KA,Verma S,et al.Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy[J].J Clin Oncol,2010,28(7):1138-1144.
34 Scott GK,Goga A,Bhaumik D,et al.Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b[J].J Biol Chem,2007,282(2):1479-1486.
35 Leivonen SK,Sahlberg KK,Makela R,et al.High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth[J].Mol Oncol,2014,8(1):93-104.
36 Gong C,Yao Y,Wang Y,et al.Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer[J].J Biol Chem,2011,286(21):19127-19137.
37 Iorio MV,Casalini P,Piovan C,et al.MicroRNA-205 regulates HER3 in human breast cancer[J].Cancer Res,2009,69(6):2195-2200.
38 Venturutti L,Cordo Russo RI,Rivas MA,et al.MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1[J].Oncogene,2016,35(48):6189-6202.
39 Corcoran C,Rani S,Breslin S,et al.miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer[J].Mol Cancer,2014,13:71.

[1]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[2]	李烁,张楠楠,李亮亮,龙志平,尹慧慧,赵亚双,王帆. 外周血白细胞PDE4C基因甲基化及环境因素交互作用与乳腺癌发病的关系[J]. 实用肿瘤学杂志, 2019, 33(3): 233-238.
[3]	李嘉琪,栾瑾微,张,玉,李香兰. 763例三阴性乳腺癌临床病理特征及复发、转移影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(3): 244-249.
[4]	陈艳波, 孔德嘉, 张金锋, 马志刚. 乳腺癌患者CYP2D6基因多态性与他莫昔芬代谢相关性研究[J]. 实用肿瘤学杂志, 2019, 33(2): 110-114.
[5]	吕博文, 钱钧, 王杰, 钱景荣, 卢莹莹, 苏丽菊, 杨桐树, 李文辉. miR-455-5p在上皮性卵巢癌中表达研究及其靶基因功能分析[J]. 实用肿瘤学杂志, 2019, 33(2): 115-121.
[6]	孙江宏, 郝明珠, 姜丹, 国飞, 李晓梅. 乳腺炎、良性增生及乳腺癌FFDM鉴别诊断思路[J]. 实用肿瘤学杂志, 2019, 33(2): 139-141.
[7]	马志杰, 王帆, 赵亚双. 乳腺癌化疗患者生存质量及影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(2): 149-154.
[8]	马质莹, 尚乃舰, 蔡妙田, 沈阳, 姜智允. 孕激素及雌激素受体阳性乳腺癌HER-2受体与钼靶影像学特征及临床病理学特征的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 47-51.
[9]	何煦, 叶尚勉, 董丹丹, 李科. HLA-G在乳腺癌中的表达及意义[J]. 实用肿瘤学杂志, 2018, 32(5): 410-414.
[10]	林荣杰, 尹航, 周云峰. ON123300对ER阳性人乳腺癌MCF-7细胞的影响及机制研究[J]. 实用肿瘤学杂志, 2018, 32(3): 193-197.
[11]	李林(综述), 李志高(审校). 二甲双胍与不同分子亚型乳腺癌的关系[J]. 实用肿瘤学杂志, 2018, 32(3): 267-270.
[12]	郑伟, 许守平, 庞达. 长链非编码RNA Linc00152在泛癌中表达、预后及功能研究[J]. 实用肿瘤学杂志, 2018, 32(1): 7-13.
[13]	殷玉莲, 张卫红, 周悦, 叶媚娜, 陈红风. ERα基因单核苷酸多态性与乳腺癌应用芳香化酶抑制剂引发骨丢失的相关性研究[J]. 实用肿瘤学杂志, 2018, 32(1): 14-18.
[14]	苗素平, 郭二亮, 裴荣, 姜寰宇, 苗素生. miRNA调节免疫检查点在肿瘤治疗中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 57-62.
[15]	黎玉娇, 尚乃舰. 影像学评估乳腺癌新辅助化疗反应的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 63-67.